Debate Series - Estro-events.org

prE-MEETinG CoUrsEs
Radiobiology
COMBINING RADIATION WITH TARGETED THERAPIES:
CONCEPTS, OPPORTUNITIES AND PITFALLS
COuRSE diRECTORS: C. Vens (NL) and A. Chalmers (UK)
WEDNESDAY, 9 MAY 2012
9:00 – 17:00 • ROOM 118-119
COuRSE aimS
Research into the mechanisms underlying resistance of tumours to radiation therapy
has identified a number of key pathways that could be targeted in order to improve
tumour control. And advances in drug development have provided us with new drugs
to manipulate these pathways. But only a few of these targeted agents have been
successfully combined with radiation therapy in the clinic, and the results have been
mixed. The aim of this course is to provide an overview of the key concepts and pathways
involved, and to discuss progress made and problems encountered in bringing
radiation/targeted therapy combinations to the clinic.
WhO ShOuld aTTEnd ThE COuRSE?
The course is targeted at radiation oncologists who may be aware of the existence
of targeted therapies, and may even have prescribed them, but would like to learn
more. In particular we will try to explain why and how these agents can be combined
with radiation therapy. Research or scientific experience is not required, but the
course will also be of interest to scientists undertaking radiation related research.
Page 64 PROgRammE & ExhibiTiOn guidE • ESTRO 31
PROGRAMME
09:00-09:15 > Welcome and introduction - C. Vens (NL) and A. Chalmers (UK)
09:15-09:30 > Molecular targeted agents in combination with radiotherapy – a
pharmaceutical industry perspective - O. Ataman (UK)
pArT i: Concepts and strategies
09:30-10:00 > Targeting the DNA damage response - A. Begg (NL)
10:00-10:30 > Targeting radiation induced signal transduction pathways
- G. Higgins (UK)
10:30-11:00 > Coffee break
11:00-11:30 > Targeting the microenviroment to enhance tumour radiation responses
- N. Cordes (DE)
11:30-12:00 > Combining radiation with agents that target angiogenesis and
vasculogenesis - E. Hammond (UK)
pArT ii: promises and limitations
12:00-12:30 > What to target and who to include? - K. Harrington (UK)
12:30-13:00 > Lunch
13:30-14:00 > Targeted therapy biomarkers for patient individualization
- M. O’Connor (UK)
14:00-14:30 > Biomarkers of radiation response - D. Zips (DE)
pArT iii: Towards the clinic
14:30-15:00 > The radiation oncologist’s perspective: hopes and fears
- R. Simcock (UK)
15:00-15:30 > Coffee Break
15:30-16:00 > Exploiting opportunities: how to design RT combination trials?
- A. Chalmers (UK)
pArT iV: The future
16:00-16:45 > Combining targeted radiation with targeted agents – a vision for the
future... - T. Lawrence (USA)
16:45-17:00 > Final discussion and concluding remarks
- Anthony Chalmers (UK) and C. Vens (NL)
ESTRO 31 • PROgRammE & ExhibiTiOn guidE Page 65
prE-MEETinG CoUrsEs